MAB5212
Anti-Neurocan Antibody, clone 650.24
clone 650.24, Chemicon®, from mouse
Sinônimo(s):
245 kDa Early Postnatal Core Glycoprotein
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Código UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Produtos recomendados
fonte biológica
mouse
Nível de qualidade
forma do anticorpo
purified immunoglobulin
tipo de produto de anticorpo
primary antibodies
clone
650.24, monoclonal
reatividade de espécies
rat
fabricante/nome comercial
Chemicon®
técnica(s)
immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
Isotipo
IgG1
nº de adesão NCBI
nº de adesão UniProt
Condições de expedição
wet ice
modificação pós-traducional do alvo
unmodified
Informações sobre genes
human ... NCAN(1463)
Descrição geral
Neurocan is the major soluble chondroitin sulfate proteoglycan in the brain. It is thought to play a functional role in axonal growth and guidance and in the establishment of specific neural pathways during embryonic brain development. Neurocan expression in the brain is developmentally regulated. Early on the major form of neurocan consists of a 245 kD core protein with approximately two chondroitin sulfate glycosoaminoglycan chains of 22 kD each. Later neurocan comprises a 180 kD core protein. Both forms of neurocan contain only chondroitin 4-sulfate glycosoaminoglycan chains. By virtue of their high expression at sites of neurnal damage and trauma, chondroitin sulfate proteoglycans, including neurocan, are thought to inhibit successful nerve regeneration.
Especificidade
Neurocan. The specificity of clone 650.24 was checked by western blots of brain lysates and purified neurocan; the antibody reacted with the identical bands that clones 1D1 and 1F6 (other neurocan monoclonals) reacted; furthermore, the staining pattern of brain sections with these antibodies were all identical. Finally 650.24 also recognized recombinant neurocan expressed in transfected 293 cells by western blot.
Imunogênio
Embryonic rat brain proteoglycans
Aplicação
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neuroregenerative Medicine
Growth Cones & Axon Guidance
Neuroregenerative Medicine
Growth Cones & Axon Guidance
This Anti-Neurocan Antibody, clone 650.24 is validated for use in IP, WB, IC, IH for the detection of Neurocan.
Western blot: 1-2 μg/mL. Reacts with polypeptides of 260 and 160 kDa on western blots of embryonic rat brain tissue extracts. The 160 kDa species is typically only seen aftyer chondroitinase treatment.Treatment is at a concentration of chondroitinase of 10U/mL in Tris-HCL pH 8.0. Make tissue or cell extract in 20-50mM Tris pH 7.6-8.0 with 0.15M NaCl in the presence of protease inhibitors. Add 1 microliter of enzyme to 30 microliters of extract and incubate 30 minutes at 37C. Then add SDS sample buffer, heat or boil sample as normal for SDS reducing samples.
Immunocytochemistry: 1:5
Immunohistochemistry on 4% paraformaldehyde fixed tissue: 1:1,000
Immunoprecipitation: 1-2 μg/mL
Optimal working dilutions must be determined by the end user.
Immunocytochemistry: 1:5
Immunohistochemistry on 4% paraformaldehyde fixed tissue: 1:1,000
Immunoprecipitation: 1-2 μg/mL
Optimal working dilutions must be determined by the end user.
forma física
Format: Purified
Purified immunoglobulin. Liquid in 0.02M Phosphate buffer, 0.25M NaCl with 0.1% sodium azide.
Armazenamento e estabilidade
Maintain at 2-8°C in undiluted aliquots for up to 6 months.
Nota de análise
Control
POSITIVE CONTROL:
early post-natal rat brain. Not expressed in kidney, lung, liver, or muscle.
POSITIVE CONTROL:
early post-natal rat brain. Not expressed in kidney, lung, liver, or muscle.
Outras notas
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Informações legais
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Exoneração de responsabilidade
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Ferramenta de seleção de produtos.
Código de classe de armazenamento
10 - Combustible liquids
Classe de risco de água (WGK)
WGK 2
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Certificados de análise (COA)
Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Alterations in chondroitin sulfate proteoglycan expression occur both at and far from the site of spinal contusion injury.
Andrews, EM; Richards, RJ; Yin, FQ; Viapiano, MS; Jakeman, LB
Experimental neurology null
Marc R Del Bigio et al.
Cerebrospinal fluid research, 5, 12-12 (2008-07-12)
The cerebral cortex may be compressed in hydrocephalus and some experiments suggest that movement of extracellular substances through the cortex is impaired. We hypothesized that the extracellular compartment is reduced in size and that the composition of the extracellular compartment
Frauke Seehusen et al.
PloS one, 11(7), e0159752-e0159752 (2016-07-22)
In demyelinating diseases, changes in the quality and quantity of the extracellular matrix (ECM) may contribute to demyelination and failure of myelin repair and axonal sprouting, especially in chronic lesions. To characterize changes in the ECM in canine distemper demyelinating
James M Massey et al.
Experimental neurology, 209(2), 426-445 (2007-06-02)
Increased chondroitin sulfate proteoglycan (CSPG) expression in the vicinity of a spinal cord injury (SCI) is a primary participant in axonal regeneration failure. However, the presence of similar increases of CSPG expression in denervated synaptic targets well away from the
Wu-Fu Chen et al.
CNS neuroscience & therapeutics, 21(9), 698-707 (2015-07-21)
To date, no reliable methods have proven effective for treating spinal cord injury (SCI). Even systemic administration of methylprednisolone (MP) remains controversial. We previously reported that intrathecal (i.t.) administration of granulocyte colony-stimulating factor (G-CSF) improves outcome after experimental spinal cord
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica